Windtree Therapeutics (NASDAQ:WINT) Announces Earnings Results, Misses Expectations By $12.80 EPS

Windtree Therapeutics (NASDAQ:WINT) announced its earnings results on Monday. The company reported ($20.91) EPS for the quarter, missing analysts’ consensus estimates of ($8.11) by ($12.80), Zacks reports.

Windtree Therapeutics Stock Up 2.0 %

WINT opened at $11.22 on Wednesday. The firm has a market cap of $6.64 million, a P/E ratio of -0.31 and a beta of 0.55. The business’s fifty day simple moving average is $5.81 and its 200 day simple moving average is $5.71. Windtree Therapeutics has a 52 week low of $2.81 and a 52 week high of $27.00.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.